In the Journals Plus

Azacitidine-nivolumab combination safe, effective in certain patients with acute myeloid leukemia

November 20, 2018
The combination of azacitidine and nivolumab appeared associated with encouraging response rates and survival outcomes among patients with relapsed…

Durvalumab alone or with tremelimumab fails to extend OS in metastatic lung cancer

November 16, 2018
A randomized phase 3 trial designed to compare durvalumab as monotherapy or in combination with tremelimumab with standard platinum-based…

Pembrolizumab extends OS in PD-L1-expressing esophageal cancers

November 14, 2018
A randomized phase 3 trial designed to compare pembrolizumab with chemotherapy as second-line treatment of advanced or metastatic esophageal or…
Meeting News

Adverse effects from certain immunotherapies may be more common than initially reported

November 13, 2018
Adverse events associated with immune checkpoint inhibitors may be more common than reported in trials that led to FDA approvals of those agents…
FDA News

FDA grants priority review to Tecentriq combination for advanced triple-negative breast cancer

November 13, 2018
The FDA granted priority review to a supplemental biologics license application that seeks approval of atezolizumab in combination with…
Meeting News

Nivolumab benefit in advanced head and neck cancer maintained regardless of age

November 9, 2018
NEW YORK — The OS benefit observed with nivolumab compared with investigator’s choice of single-agent chemotherapy for patients with…
Meeting News

Immune-related adverse events manageable with vigilance, appropriate treatment

November 8, 2018
NEW YORK — Advances in immunotherapy have transformed cancer treatment but require clinicians to be vigilant for adverse events, according to a…
Meeting News

Triple combination appears safe, effective for advanced BRAF V600-mutant melanoma

November 8, 2018
NEW YORK — The addition of spartalizumab to dabrafenib and trametinib appeared safe and effective for previously untreated patients with…
In the Journals Plus

Elotuzumab combination extends PFS for certain patients with relapsed, refractory multiple myeloma

November 7, 2018
The addition of the elotuzumab to pomalidomide and dexamethasone conferred a significant PFS benefit among certain patients with relapsed or…
FDA News

FDA approves triplet regimen for relapsed, refractory myeloma

November 6, 2018
The FDA approved elotuzumab plus pomalidomide and dexamethasone for treatment of adults with relapsed or refractory multiple myeloma. The triplet…